News for Ultragenyx Pharmaceutical Inc. (0LIF.L)

Summary Ultragenyx Pharmaceutical Inc (RARE), a company dedicated to developing therapies for rare and ultrarare diseases, announced on April 22, 2025, the gran

NOVATO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. ( RARE), a biopharmaceutical company focused on the development and commerci

**media[602319]**

Bank of America has revised its price target for Ultragenyx Pharmaceutical Inc. (RARE), reducing it from $83 to $80, while maintaining its Buy rating on the sto

We recently published a list of Billionaire Stanley Druckenmiller’s Top 10 Stocks Picks with Huge Upside Potential. In this article, we are going to take a look at where Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stands against other Billionaire Stanley Druckenmiller’s top stock picks with huge upside potential. Wall Street is overflowing with data. If companies are […]

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stands against the other best mid cap biotech stocks to buy. Is the Biotech Sector Oversaturated? On March 6, Jared Holz, Mizuho health care […]

Summary Ultragenyx Pharmaceutical Inc (RARE), a biopharmaceutical company dedicated to developing therapies for rare and ultrarare diseases, announced on March

NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. ( RARE), a biopharmaceutical company focused on the development and commerci

**media[571392]**

The ClearBridge SMID Cap Growth Strategy outperformed its Russell 2500 Growth Index benchmark during the fourth quarter. Click here to read the full commentary.

LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc ( MREO) (”œMereo” or the ”œCompany”), a clinical-stage biopharmaceutical company fo

Summary Ultragenyx Pharmaceutical Inc (RARE), a biopharmaceutical company dedicated to developing therapies for rare and ultrarare genetic diseases, announced o

NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. ( RARE), a biopharmaceutical company focused on the development and commercia

**media[545030]**

Summary Ultragenyx Pharmaceutical Inc (RARE) has announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA)

FDA decision expected by August 18, 2025 NOVATO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. ( RARE) today announced the U.S. F

The following slide deck was published by Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ETCompany ParticipantsJoshua Higa - VP, IREmil...

**media[540325]**